OTC · IMVIQ
Healthcare · Biotechnology
$0.00
Down-$0.00 (-90.91%)
Updated Aug 16, 2026, 2:38 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
IMVIQ does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning IMVIQ.
IMVIQ research
Company profile and research snapshot.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
defenseworld.net · Dec 10, 2025
Earnings and Valuation This table compares NexImmune and IMV"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NexImmune N/A N/A -$32.34 million ($18.29) N/A IMV $330,000.00 0.00 -$37.99 million ($4.59) N/A NexImmune has higher earnings, but lower revenue than IMV. Risk and Volatility NexImmune has
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMVIQ.
No results
No recent SID articles mention IMVIQ.
